Researchers have achieved a medical milestone by partially restoring sight in a blind man using light-sensitive proteins introduced into his retina. This groundbreaking study, published in Nature Medicine, marks the first successful human application of this approach.
The 58-year-old French volunteer now perceives ghostly outlines of objects through a limited field of vision with specialized glasses—a vast improvement over total blindness. "It's not the end of the journey, but a major milestone," says Dr. José-Alain Sahel, who leads research at the University of Pittsburgh and Sorbonne University in Paris. After 13 years of dedicated work, this proof-of-concept paves the way for advanced treatments.
Vision begins when the retina—a thin layer of neurons at the back of the eye—detects and converts light into electrical signals, much like a camera sensor. Photoreceptor cells form a mosaic that captures visible light, but signals pass through five layers of cells before ganglion cells send them via the optic nerve to the brain.
Retinitis pigmentosa, an inherited condition affecting over two million people worldwide, destroys these photoreceptors, often leading to complete blindness. Scientists have long targeted this devastating disease.
Dr. Sahel's team used gene therapy to convert retinal ganglion cells into functional photoreceptors by introducing proteins from algae and microbes that make neurons light-sensitive—a technique known as optogenetics.
Optogenetics emerged in the early 2000s, when researchers used viruses to deliver these genes into animal brain cells, enabling precise control with light to map neural circuits and behaviors.
Here, the team adapted it to add photosensitive proteins directly to retinal ganglion cells.
Standard optogenetic proteins weren't sensitive enough for natural light, so the researchers selected ones responsive to amber light. Viruses delivered these to the patient's ganglion cells.
They developed prosthetic glasses with a device that converts real-world visuals into amber light patterns, compensating for the eye's constant micro-movements.
After successful monkey trials, the team injected the therapy into human volunteers, waiting months for proteins to integrate before training with the glasses.
Delayed by the pandemic, the trial proceeded with one 58-year-old volunteer from Brittany. After seven months of daily glasses use, he spotted white crosswalk stripes—a thrilling breakthrough.
Lab tests confirmed he could touch a notebook on a table and correctly count cups 12 out of 19 times.
While more trials are essential for broader validation, this progress signals hope. Dr. Sahel's team is now recruiting for expanded studies to refine the therapy and glasses.
